Leadless Pacemakers: Aveir VR vs. Micra
Leadless pacemakers eliminate the transvenous lead and surgical pocket — historically the two largest sources of long-term pacemaker complications. Two systems dominate the market today: the Medtronic Micra family (the original commercially successful leadless device) and Abbott's Aveir platform, designed from the ground up for chronic retrievability and, in its dual-chamber configuration, AV-synchronous leadless pacing.
This article compares the two systems on the dimensions that matter clinically: fixation mechanism, retrievability, communication architecture, battery longevity, dual-chamber capability, and the patient populations where each tends to be selected.
At-a-glance comparison
| Attribute | Aveir VR (Abbott) | Micra VR / Micra AV (Medtronic) |
|---|---|---|
| Fixation | Active helix (screw-in) | Passive nitinol tines |
| Chronic retrievability | Designed for full chronic retrieval | Acute retrieval only; chronic retrieval not labeled |
| Dual-chamber capability | Yes, via Aveir AR + i2i communication | Single-chamber; Micra AV adds mechanical AV synchrony via accelerometer |
| Inter-device communication | i2i conducted (implant-to-implant) | None (single device) / accelerometer-based sensing (Micra AV) |
| Mapping prior to fixation | Yes — pacing/sensing can be assessed before fixation deployed | Limited — fixation occurs at deployment |
| Battery longevity (projected, nominal) | ~15–20 years | ~8–12 years |
| Delivery catheter | 27 F introducer | 27 F introducer |
| MRI compatibility | Conditional | Conditional |
The Medtronic Micra family
Mechanism and fixation
The Micra is a self-contained pacing capsule fixed to the right ventricular endocardium by four flexible nitinol tines. The tines engage trabeculation passively as the device is pushed against the wall; fixation is confirmed via the pull-and-hold test and a tug stability maneuver under fluoroscopy. Once the tines are engaged and endothelialization begins (typically within weeks), the device becomes encapsulated and is no longer considered retrievable through standard means.
Micra VR vs. Micra AV
Micra VR provides VVI(R) pacing. Micra AV adds an accelerometer-based algorithm that detects atrial mechanical contraction (the A4 signal), allowing the device to deliver VDD-like AV-synchronous pacing in patients with intact sinus node function and AV block. This is mechanical, not electrical, atrial sensing — performance depends on patient hemodynamics, posture, and activity level.
Where Micra is commonly selected
- Patients needing single-chamber ventricular pacing with limited expected longevity demands.
- Patients with prior transvenous lead infections or compromised venous access.
- Patients on hemodialysis where preserving upper-extremity vasculature is a priority.
- Patients who decline a transvenous system on cosmetic or lifestyle grounds.
The Abbott Aveir platform
Helix-based fixation and mapping
The Aveir VR uses an active helix that screws into the myocardium. Unlike a tined design, the helix permits pacing and sensing to be measured before the device is permanently fixed — if values are poor, the operator can withdraw, reposition, and re-deploy without using a second device. This "map-before-fix" workflow is one of the most distinctive features of the platform.
Chronic retrievability
The helix is designed to be unscrewed at end-of-life, allowing the device to be removed and replaced through a catheter-based approach. While retrieval is procedurally demanding and not without risk, it is a labeled capability — distinguishing Aveir from the Micra family, where chronic retrieval is not part of the device's intended use.
Dual-chamber leadless pacing (Aveir DR)
When implanted together with the Aveir AR atrial leadless device, the Aveir VR participates in beat-to-beat conducted communication called i2i — implant-to-implant. The atrial and ventricular devices exchange short high-frequency electrical signals through the blood pool with each cardiac cycle, enabling true AV-synchronous dual-chamber pacing without leads. The trade-off is increased current draw associated with continuous i2i, which is accounted for in the device's battery accounting.
Where Aveir tends to be selected
- Younger patients in whom the option of later retrieval and replacement is valued.
- Patients needing dual-chamber pacing who would otherwise be candidates for a transvenous dual-chamber system but want to avoid leads.
- Operators who prefer the "map before fix" workflow.
- Cases where projected longevity matters disproportionately (e.g., expected high pacing burden).
Clinical considerations when choosing between them
Anatomy and access
Both systems deploy through a femoral 27 F introducer and both are MRI conditional. Femoral venous access, IVC anatomy, RV chamber size, and trabecular pattern can influence implant difficulty for either device, but neither has a clear advantage on access alone.
Pacing burden and physiology
High RV pacing burden has long been associated with pacing-induced cardiomyopathy (PICM). Patients projected to have a high RV pacing burden — particularly those with reduced baseline LV function — may benefit more from a dual-chamber strategy (Aveir DR) or, depending on the indication, from conduction system pacing rather than any leadless RV-only option.
End-of-life planning
Micra is typically left in place at end-of-life and a second device is implanted alongside it; up to three Micra devices in the RV have been reported in registry data. Aveir is intended to be retrieved and replaced. The implications for younger patients with decades of expected pacing ahead are obvious — but retrieval is not free of procedural risk and should not be assumed to be routine in any individual case.
Evidence base in brief
Both devices have substantial published evidence, including pivotal investigational device exemption (IDE) trials, post-approval registries, and a growing body of real-world comparative data. Micra has the longer and larger real-world footprint by virtue of its earlier approval; Aveir has a smaller but rapidly accumulating evidence base, particularly around dual-chamber leadless pacing performance (the AVEIR DR i2i study). Reading the original trial publications and current registry updates is recommended before incorporating either platform into a new program.
Frequently asked questions
What is the main clinical difference between Aveir VR and Micra?
Retrievability and dual-chamber capability. Aveir VR is designed for chronic retrieval and is the ventricular component of a true leadless dual-chamber system (Aveir DR). Micra is implanted with the expectation it will remain in place; Micra AV provides AV-synchronous pacing through accelerometer-based mechanical sensing rather than electrical atrial sensing.
Can either device pace the conduction system (LBBAP)?
No. Both devices are RV myocardial pacing systems. Conduction system pacing — including left bundle branch area pacing (LBBAP) — currently requires a transvenous lead approach. Leadless conduction-system pacing is an active area of research but not commercially available.
How long do these devices last?
Manufacturer-projected longevity at nominal settings places Aveir VR in roughly the 15–20 year range and the Micra family in roughly the 8–12 year range. Real-world longevity depends heavily on pacing burden, output, and impedance, and will be shorter under demanding conditions.
Is the device visible on chest X-ray or echocardiogram?
Yes. Both devices are radio-opaque and clearly visible on chest X-ray. On transthoracic echocardiography the capsule is usually seen in the RV apex or septum; transesophageal echocardiography offers better visualization of fixation site and any pericardial effusion in the periprocedural period.
What are the most important complications to know about?
The most clinically important early complications are cardiac perforation and pericardial effusion (more common in older, thinner-walled patients and with septal positioning), vascular access complications at the femoral site, and device dislodgement. Late complications include capture threshold rise, battery depletion, and, rarely, device-associated thrombus. Periprocedural mortality is low in registry data but non-zero.
Are leadless pacemakers MRI compatible?
Both Aveir VR and the Micra family are MRI conditional. Scans require following the manufacturer's specific MRI conditions, including scanner field strength, scan region, and device programming around the scan.
References and further reading
- Reynolds D, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. (Micra IDE pivotal trial.)
- Reddy VY, et al. Primary Results on Safety and Efficacy from the LEADLESS II — Phase 2 Investigational Device Exemption Study of the Aveir Leadless Pacemaker. Circulation.
- Knops RE, et al. A Dual-Chamber Leadless Pacemaker (AVEIR DR i2i study). N Engl J Med.
- Steinwender C, et al. Atrioventricular Synchronous Pacing Using a Leadless Ventricular Pacemaker (MARVEL studies — Micra AV).
- El-Chami MF, et al. Real-world performance of the Micra transcatheter pacing system — post-approval registry analyses.
- Abbott Aveir VR/AR/DR Instructions for Use (latest revision).
- Medtronic Micra VR / Micra AV Instructions for Use (latest revision).
Related topics on ABC Farma
- Left Bundle Branch Area Pacing (LBBAP) — Technique & Outcomes (coming soon)
- Pacing-Induced Cardiomyopathy — Risk & Reversal (coming soon)
- Capture Threshold Physiology & Exit Block (coming soon)
- Phrenic Nerve Stimulation in Leadless Pacemakers (coming soon)
- Echocardiographic Surveillance of Paced Patients (coming soon)